Zymeworks Inc. (ZYME)

USD 12.74

(-4.71%)

Total Assets Summary of Zymeworks Inc.

Zymeworks Inc.'s latest annual total assets in 2023 was 580.88 Million USD , down -10.46% from previous year.
Zymeworks Inc.'s latest quarterly total assets in 2024 Q3 was 487.15 Billion USD , down -5.52% from previous quarter.
Zymeworks Inc. reported annual total assets of 648.72 Million USD in 2022, up 66.71% from previous year.
Zymeworks Inc. reported annual total assets of 389.13 Million CAD in 2021, down -27.72% from previous year.
Zymeworks Inc. reported quarterly total assets of 515.63 Million USD for 2024 Q2, down -6.88% from previous quarter.
Zymeworks Inc. reported quarterly total assets of 487.15 Billion USD for 2024 Q3, down -5.52% from previous quarter.

Annual Total Assets Chart of Zymeworks Inc. (2023 - 2014)

Historical Annual Total Assets of Zymeworks Inc. (2023 - 2014)

Year	Total Assets	Total Assets Growth
2023	580.88 Million USD	-10.46%
2022	648.72 Million USD	66.71%
2021	389.13 Million CAD	-27.72%
2020	538.37 Million USD	46.22%
2019	368.2 Million USD	50.68%
2018	244.36 Million USD	85.19%
2017	131.95 Million USD	40.39%
2016	93.99 Million USD	306.04%
2015	23.14 Million USD	-54.32%
2014	50.68 Million USD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q1	553.75 Million USD	-4.67%
2024 Q2	515.63 Million USD	-6.88%
2024 Q3	487.15 Billion USD	-5.52%
2023 Q1	600.74 Million USD	-7.4%
2023 FY	580.88 Million USD	-10.46%
2023 Q4	580.88 Million USD	4.41%
2023 Q3	556.36 Million USD	-7.59%
2023 Q2	602.05 Million USD	0.22%
2022 Q4	648.72 Million USD	116.05%
2022 FY	648.72 Million USD	66.71%
2022 Q3	300.26 Million USD	-18.62%
2022 Q1	429.97 Million USD	10.5%
2022 Q2	368.96 Million USD	-14.19%
2021 FY	389.13 Million CAD	-27.72%
2021 Q4	389.13 Million CAD	-7.43%
2021 Q3	420.36 Million USD	-10.93%
2021 Q1	490.05 Million USD	-8.97%
2021 Q2	471.95 Million USD	-3.69%
2020 Q2	606.85 Million USD	-4.67%
2020 Q4	538.37 Million USD	-5.83%
2020 Q1	636.57 Million USD	72.89%
2020 Q3	571.71 Million USD	-5.79%
2020 FY	538.37 Million USD	46.22%
2019 Q4	368.2 Million USD	-7.96%
2019 Q3	400.03 Million USD	-3.5%
2019 Q2	414.54 Million USD	73.98%
2019 Q1	238.27 Million USD	-2.49%
2019 FY	368.2 Million USD	50.68%
2018 Q1	113.53 Million USD	-13.96%
2018 Q2	210.99 Million USD	85.84%
2018 Q3	194.44 Million USD	-7.85%
2018 Q4	244.36 Million USD	25.68%
2018 FY	244.36 Million USD	85.19%
2017 FY	131.95 Million USD	40.39%
2017 Q4	131.95 Million USD	32.32%
2017 Q3	99.72 Million USD	-12.94%
2017 Q2	114.54 Million USD	43.09%
2017 Q1	80.05 Million USD	-14.83%
2016 Q3	98.48 Million USD	0.0%
2016 Q1	- USD	-100.0%
2016 Q4	93.99 Million USD	-4.56%
2016 FY	93.99 Million USD	306.04%
2015 Q4	23.14 Million USD	0.0%
2015 FY	23.14 Million USD	-54.32%
2014 FY	50.68 Million USD	0.0%

Peer Total Assets Comparison of Zymeworks Inc.

Name	Total Assets	Total Assets Difference
ADC Therapeutics SA	354.78 Million USD	-63.729%
Alto Neuroscience, Inc.	86.62 Million USD	-570.545%
Annovis Bio, Inc.	10.2 Million USD	-5590.292%
Biohaven Pharmaceutical Holding Company Ltd.	513.21 Million USD	-13.185%
Ginkgo Bioworks Holdings, Inc.	1.66 Billion USD	65.119%
Nuvation Bio Inc.	621.48 Million USD	6.533%
Nuvation Bio Inc.	621.48 Million USD	6.533%
Arcus Biosciences, Inc.	1.09 Billion USD	46.952%
Theriva Biologics, Inc.	60.21 Million USD	-864.741%